Stock listing

NASDAQ:RLAY Relay Therapeutics, Inc. Stock

Home listing (NASDAQ) of Relay Therapeutics, Inc.

Follow Relay Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:RLAY

$16.12 USD -0.39 (-2.4%)

Close on Nov 20, 2026

Past year +152.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$15.17 – $16.32 USDNov 20, 2026
Volume
3.98M sharesNov 20, 2026
Market cap
$3.56B USDAt the close on Nov 20, 2026 · price × 221.0M shares outstanding
52-week range
$6.28 – $21.27 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$54.29M USDMedian day 2.77M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Relay Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:RLAY · Home$16.12 USD-0.39 (-2.4%)3,975,151$15.59$16.32$15.17$16.51Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RLAY · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$16.12-0.39-2.4%$15.59$16.32$15.173,975,151
$16.51+0.04+0.2%$16.41$17.14$16.232,426,042
$16.47-0.80-4.6%$17.20$17.42$16.392,569,179
$17.27-0.82-4.5%$17.81$18.07$17.221,651,500
$18.09+0.01+0.1%$17.95$18.25$17.281,478,164
$18.08-1.64-8.3%$19.51$19.51$18.052,764,336
$19.72-0.22-1.1%$20.01$20.21$19.691,932,007
$19.94-0.45-2.2%$20.00$20.96$19.652,402,109
$20.39+1.79+9.6%$19.08$20.64$18.713,847,791
$18.60+1.60+9.4%$17.14$18.72$16.663,194,720
$17.00-1.03-5.7%$17.71$18.21$16.534,720,932
$18.03+0.59+3.4%$17.57$18.27$17.083,729,806
$17.44+0.16+0.9%$17.52$18.00$17.283,176,095
$17.28-1.07-5.8%$18.39$18.51$17.242,853,981
$18.35-1.12-5.8%$19.09$19.48$18.013,595,892
$19.47-0.22-1.1%$19.80$20.20$19.311,944,976
$19.69+0.85+4.5%$18.62$19.71$18.602,807,593
$18.84+0.72+4.0%$18.18$18.95$17.822,258,106
$18.12-0.06-0.3%$18.33$18.66$17.971,585,695
$18.18-0.16-0.9%$18.03$18.27$17.681,898,900
$18.34-0.07-0.4%$18.28$18.71$18.021,722,000
$18.41-0.04-0.2%$18.61$19.03$18.191,598,200
$18.45+1.36+8.0%$17.03$18.69$17.011,976,100
$17.09+0.81+5.0%$16.53$17.21$16.381,748,700
$16.28-1.02-5.9%$17.17$17.17$16.132,366,600
$17.30+0.24+1.4%$17.15$17.56$17.072,117,100
$17.06-0.30-1.7%$17.02$17.77$16.902,936,800
$17.36-0.62-3.4%$17.84$17.94$17.271,706,400
$17.98+0.10+0.6%$17.77$18.33$17.532,091,000
$17.88+0.47+2.7%$17.01$18.50$17.011,764,500
$17.41-0.54-3.0%$17.71$17.97$16.874,332,100
$17.95-0.79-4.2%$18.40$18.54$17.853,433,000
$18.74-0.65-3.4%$19.50$19.50$18.173,879,800
$19.39+0.43+2.3%$19.00$19.40$18.292,936,000
$18.96+0.47+2.5%$18.71$19.13$18.602,771,000
$18.49+0.44+2.4%$18.02$19.08$17.862,824,200
$18.05-0.31-1.7%$18.39$18.72$17.932,782,500
$18.36+0.67+3.8%$17.65$18.48$17.523,589,000
$17.69+0.22+1.3%$17.10$17.88$17.051,843,500
$17.47-0.26-1.5%$17.94$18.01$17.422,983,600
$17.73-0.30-1.7%$18.09$18.09$17.413,675,000
$18.03-1.32-6.8%$19.15$19.23$17.224,705,600
$19.35+1.16+6.4%$18.43$19.48$18.213,632,000
$18.19-0.65-3.5%$19.07$19.17$18.053,029,900
$18.84-0.35-1.8%$19.25$19.40$18.6810,076,100
$19.19+0.35+1.9%$19.45$19.69$19.073,095,700
$18.84-0.13-0.7%$18.97$19.22$18.622,116,700
$18.97-0.09-0.5%$19.05$19.09$18.642,742,800
$19.06+0.19+1.0%$18.90$19.43$18.882,400,200
$18.87-0.02-0.1%$19.17$19.35$18.684,164,400
$18.89+0.23+1.2%$18.30$19.11$18.103,000,700
$18.66-0.45-2.4%$18.76$19.19$18.546,061,100
$19.11+0.07+0.4%$18.78$19.28$18.315,029,400
$19.04+0.03+0.2%$18.85$19.26$18.682,054,800
$19.01+0.50+2.7%$18.55$19.10$18.342,716,600
$18.51+0.02+0.1%$18.70$19.27$18.292,107,900
$18.49+0.11+0.6%$18.15$18.68$17.961,598,400
$18.38-0.39-2.1%$18.54$18.64$18.033,784,700
$18.77-0.65-3.3%$19.15$19.30$18.632,762,900
$19.42-0.04-0.2%$19.23$19.68$19.162,394,400
$19.46-1.11-5.4%$19.95$20.12$19.192,936,600
$20.57+0.81+4.1%$20.18$20.77$20.052,744,194
$19.76+0.32+1.6%$19.16$20.03$18.602,639,387
$19.44-0.26-1.3%$19.92$20.17$19.182,965,800
$19.70-1.04-5.0%$20.36$20.50$19.422,788,700
Ticker
NASDAQ:RLAY
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Relay Therapeutics, Inc. news

Relay Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
17 in the last 12 months · 112 in all · newest Nov 4, 2026 · oldest 2020
Decks
25 decks · latest August 2026

Where Relay Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:RLAY · Home listing · This pageNASDAQUnited StatesUSD
BOATS:RLAYBOATSUnited StatesUSD

Valuation

EV/sales 265× against a median of 83.7×: the highest of 4 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$2.74B USD
P/E
Loss
EV/sales
265×
EV/EBITDA
Negative EBITDA
Price/book
4.3×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta vs S&P 500
1.48

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Relay Therapeutics, Inc. · NASDAQ:RLAYUS$3.56BUS$2.74Bn/a265×n/a4.3×n/a0.0×1.48
CRISPR Therapeutics AG · NASDAQ:CRSPUS$3.79BUS$2.11Bn/a83.7×n/a2.3×n/a0.4×1.64
Tango Therapeutics, Inc. · NASDAQ:TNGXUS$3.68BUS$2.74Bn/an/an/a3.8×n/a0.0×1.41
Xenon Pharmaceuticals Inc. · NASDAQ:XENEUS$3.64BUS$2.70Bn/an/an/a3.2×n/a0.0×0.80
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Class A · SSE:688336US$3.56BUS$3.42B7.6×5.1×n/a2.7×69.9%0.0×n/a
Enliven Therapeutics, Inc. · NASDAQ:ELVNUS$3.42BUS$2.54Bn/an/an/a3.9×n/a0.0×0.89
Disc Medicine, Inc. · NASDAQ:IRONUS$3.42BUS$2.80Bn/an/an/a5.7×n/a0.1×0.94
Viridian Therapeutics, Inc. · NASDAQ:VRDNUS$3.40BUS$2.69Bn/a102×n/a5.9×n/a0.4×1.00
Parabilis Medicines, Inc. · NASDAQ:PBLSUS$3.39BUS$2.53Bn/an/an/a3.4×n/a0.0×n/a
Caliway Biopharmaceuticals Co Ltd · TWSE:6919US$3.38BUS$3.27Bn/an/an/a12.7×n/a0.0×n/a
Amylyx Pharmaceuticals, Inc. · NASDAQ:AMLXUS$3.35BUS$2.58Bn/an/an/a4.4×n/a0.0×1.21
Median of the othersUS$3.42BUS$2.69B7.6×83.7×3.8×69.9%0.0×1.00

Forecasts

9 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
28.25 USD · Analysts' mean
EPS, year to Dec 2026
-1.56 · 11 analysts
Revenue, year to Dec 2026
6.9M · 11 analysts

Team and board

OfficerRole
Sanjiv K. PatelPresident & Chief Executive Officer
Tom CatinazzoChief Financial Officer
Don BergstromPresident, R&D
Imogen PryceChief Operating Officer, R&D
Soo-Yeun LimSenior Vice President, General Counsel
Eunice KwakSVP, Breast Cancer Global Medical Lead
Jim WattersChief Scientific Officer
Mahesh PadvalChief Pharmaceutical Development Officer
Peter RahmerChief Corporate Development Officer
Shannon CampbellHead of Commercial

Events

QuarterResultsShare move
Q3 2026Nov 4, 2026 · After close−5.7%
Q2 2026Aug 6, 2026 · After close+0.1%
Q1 2026May 5, 2026 · After close−0.6%
Q4 2025Feb 26, 2026+11.3%
Q3 2025Nov 6, 2025 · After close−7.3%
Q2 2025Aug 7, 2025 · After close−7.7%
Q1 2025May 5, 2025 · After close−5.1%
Q4 2024Feb 20, 2025 · After close−4.2%
Q3 2024Nov 6, 2024 · After close−1.8%
Q2 2024Aug 6, 2024 · After close−7.9%
All 20 quarters
QuarterResultsShare move
Q1 2024May 2, 2024 · After close−0.6%
Q4 2023Feb 22, 2024 · After close−5.4%
Q3 2023Nov 2, 2023 · After close+1.6%
Q2 2023Aug 8, 2023 · After close+0.1%
Q1 2023May 4, 2023 · After close+0.5%
Q4 2022Feb 23, 2023 · After close−2.1%
Q3 2022Nov 3, 2022 · After close−2.1%
Q2 2022Aug 4, 2022 · After close+3.0%
Q1 2022May 5, 2022 · After close−11.5%
Q4 2021Feb 24, 2022 · After close+5.3%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (August 2026)Investor deck83 slidesAugust 2026
Technical Presentation (May 2026)Technical12 slidesMay 20, 2026
Corporate Update (May 2026)Corporate update25 slidesMay 19, 2026
Corporate Update (April 2026)Corporate update25 slidesApr 27, 2026
Technical Presentation (March 2026)Technical13 slidesMar 16, 2026
Technical Presentation (March 2026)Technical31 slidesMarch 2026
J.P. Morgan Healthcare Conference 2025Conference29 slidesJan 13, 2025
2024 San Antonio Breast Cancer Symposium (SABCS)Conference39 slidesDec 11, 2024
Corporate Update (September 2024)Corporate update34 slidesSep 9, 2024
Investor Day (June 2024)Investor day66 slidesJun 6, 2024
All 25 decks
DeckKindSlidesDate
J.P. Morgan Healthcare Conference 2024Conference32 slidesJan 8, 2024
Technical Presentation (October 2023)Technical30 slidesOct 12, 2023
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023Conference21 slidesOctober 2023
Investor Presentation (August 2023)Investor deck60 slidesAug 8, 2023
Technical Presentation (April 2023)Technical42 slidesApr 18, 2023
Technical Presentation (April 2023)Technical20 slidesApril 2023
J.P. Morgan Healthcare Conference 2023Conference51 slidesJan 9, 2023
ESMO Congress 2022Conference27 slidesSep 12, 2022
Investor Day (June 2022)Investor day50 slidesJun 27, 2022
40th Annual J.P. Morgan Healthcare Conference (January 2022)Conference43 slidesJan 10, 2022
Corporate Update (October 2021)Corporate update51 slidesOct 8, 2021
AACR-NCI-EORTC Molecular Targets Conference 2021Conference24 slidesOctober 2021
AACR-NCI-EORTC Molecular Targets Conference 2021Conference15 slidesOctober 2021
Merger or Acquisition (April 2021)Merger or acquisition14 slidesApr 16, 2021
Merger or Acquisition (December 2020)Merger or acquisition8 slidesDec 14, 2020

Open Decks

IPO

Priced at US$20.00 a share on Jul 15, 2020.

Price
US$20.00 a share
Shares offered
20,000,000 shares of common stock
Offering size
US$400 million
Underwriters' option
Up to 3,000,000 more shares
Underwriters
J.P. Morgan, Goldman Sachs & Co. LLC, Cowen, Guggenheim Securities · In the order on the cover
Shares delivered
On or about Jul 20, 2020

Steps

StepWhen
Draft sent to the SEC in confidenceMay 22, 2020
Filed publiclyJun 24, 2020
Amended 4 timesNewest Jul 15, 2020
Shares registered with an exchangeJul 13, 2020
Declared effective by the SECJul 15, 2020
Final prospectus, with the priceJul 16, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Jul 16, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue15.4M10.0M25.5M1.38M3.03M82.7M00
Cost of revenue3.56M315.4M326.4M243.0M169.4M3.55M2.85M2.15M
Gross profit11.8M-305.4M-300.8M-241.6M-166.4M79.1M-2.85M-2.15M
Research and development261.4M319.1M330.0M246.4M172.7M99.9M70.3M41.0M
Selling, general and administrative56.7M76.0M74.3M65.1M55.5M38.6M13.7M8.86M
Operating income-302.7M-372.5M-373.0M-299.3M-364.7M-55.8M-84.0M-49.9M
Depreciation and amortization3.56M5.46M5.27M4.13M3.92M3.55M2.85M2.15M
EBITDA-299.2M-367.0M-367.7M-295.1M-360.8M-52.2M-81.2M-47.7M
Interest expense8.77M826.0K000
Income before tax-276.5M-337.7M-342.0M-290.5M-363.9M-52.4M-75.3M-48.8M
Income tax00000001.10M
Net income-276.5M-337.7M-342.0M-290.5M-363.9M-52.4M-75.3M-48.8M
Earnings per share, basic-1.61-2.36-2.79-2.59-3.82-5.40-21.82-19.63
Earnings per share, diluted-1.61-2.36-2.79-2.59-3.82-5.40-21.82

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents84.0M124.3M143.7M151.8M280.1M447.6M42.0M421.5M
Short-term investments470.5M657.0M606.4M847.1M678.0M230.4M313.9M0
Receivables0306.0K403.0K75.0M
Inventory12.1M-682.5M-238.1M
Current assets578.3M809.2M770.1M1.02B976.2M770.1M360.5M424.1M
Property, plant and equipment1.73M5.91M10.9M11.6M6.54M6.25M8.09M3.63M
Total assets621.3M871.3M844.0M1.10B1.01B799.8M393.1M428.6M
Accounts payable7.71M14.1M9.21M10.6M8.28M6.35M6.99M4.71M
Current liabilities25.6M50.7M30.3M63.7M24.3M13.6M12.0M6.87M
Total debt32.5M48.5M53.5M57.7M22.9M24.4M24.8M178.0K
Total liabilities54.3M93.5M92.0M149.6M110.6M36.5M35.7M539.5M
Shareholders' equity567.1M777.8M752.0M950.2M897.8M763.3M-180.4M-110.9M
Shares outstanding173.9M167.8M127.5M121.1M108.2M89.9M4.04M2.49M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-235.5M-249.1M-300.3M-229.5M-74.4M-102.5M-66.1M-44.1M
Capital spending-410.0K-2.02M-4.13M-9.06M-3.47M-1.93M-8.00M-1.69M
Free cash flow-235.9M-251.1M-304.4M-238.6M-77.9M-104.4M-74.1M-45.8M
Cash from investing192.8M-41.1M257.6M-188.7M-479.5M81.7M-319.0M-1.68M
Cash from financing1.60M270.2M34.8M289.9M388.1M426.5M5.61M395.0M
Share buybacks1.08M1.48M1.69M5.88M429.0M5.61M-82.0K
Change in cash-41.1M-20.0M-7.93M-128.3M-165.8M405.7M-379.6M349.2M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 20, 2026Insider tradeSEC
4 · Change in ownershipNov 20, 2026Insider tradeSEC
4 · Change in ownershipNov 20, 2026Insider tradeSEC
144 · Notice of proposed saleNov 18, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 4, 2026Quarterly reportSEC
8-K · Current reportNov 4, 2026ResultsSEC
4 · Change in ownershipOct 30, 2026Insider tradeSEC
4 · Change in ownershipOct 30, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipOct 30, 2026Insider tradeSEC
4 · Change in ownershipOct 8, 2026Insider tradeSEC
4 · Change in ownershipOct 8, 2026Insider tradeSEC
144 · Notice of proposed saleOct 7, 2026Other filingsSEC
144 · Notice of proposed saleOct 6, 2026Other filingsSEC
4 · Change in ownershipSep 9, 2026Insider tradeSEC
4 · Change in ownershipSep 9, 2026Insider tradeSEC
4 · Change in ownershipSep 9, 2026Insider tradeSEC
4 · Change in ownershipAug 28, 2026Insider tradeSEC
4 · Change in ownershipAug 28, 2026Insider tradeSEC
144 · Notice of proposed saleAug 26, 2026Other filingsSEC
144 · Notice of proposed saleAug 25, 2026Other filingsSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 10, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 7, 2026Big-stake noticeSEC
424B5 · ProspectusAug 6, 2026Offer documentSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeAug 6, 2026Big-stake noticeSEC
144 · Notice of proposed saleAug 4, 2026Other filingsSEC
144 · Notice of proposed saleJul 31, 2026Other filingsSEC
4 · Change in ownershipJul 30, 2026Insider tradeSEC
4 · Change in ownershipJul 30, 2026Insider tradeSEC
4 · Change in ownershipJul 30, 2026Insider tradeSEC
144 · Notice of proposed saleJul 21, 2026Other filingsSEC
144 · Notice of proposed saleJul 20, 2026Other filingsSEC
4 · Change in ownershipJul 8, 2026Insider tradeSEC
4 · Change in ownershipJul 8, 2026Insider tradeSEC
4 · Change in ownershipJul 8, 2026Insider tradeSEC
144 · Notice of proposed saleJul 7, 2026Other filingsSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
144 · Notice of proposed saleJun 30, 2026Other filingsSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
144 · Notice of proposed saleJun 22, 2026Other filingsSEC
144 · Notice of proposed saleJun 22, 2026Other filingsSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
8-K · Current reportJun 9, 2026Meeting outcomeSEC
8-K · Current reportMay 21, 2026Material contractSEC
424B5 · ProspectusMay 21, 2026Offer documentSEC
424B5 · ProspectusMay 19, 2026Offer documentSEC
8-K · Current reportMay 19, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
144 · Notice of proposed saleMay 14, 2026Other filingsSEC
10-Q · Quarterly reportMay 5, 2026Quarterly reportSEC
8-K · Current reportMay 5, 2026ResultsSEC
4 · Change in ownershipApr 30, 2026Insider tradeSEC
4 · Change in ownershipApr 30, 2026Insider tradeSEC
4 · Change in ownershipApr 30, 2026Insider tradeSEC
ARS · Annual report to shareholdersApr 28, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2026Meeting noticeSEC
8-K · Current reportApr 27, 2026Current reportSEC
PRE 14A · Preliminary proxy statementApr 16, 2026Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeApr 13, 2026Big-stake noticeSEC
4 · Change in ownershipApr 9, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 27, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMar 19, 2026Big-stake noticeSEC
8-K · Current reportMar 16, 2026Current reportSEC
4 · Change in ownershipMar 11, 2026Insider tradeSEC
8-K · Current reportMar 11, 2026Current reportSEC
144 · Notice of proposed saleMar 9, 2026Other filingsSEC
S-8 · Registration statement for employee plansFeb 26, 2026Offer documentSEC
10-K · Annual reportFeb 26, 2026Annual reportSEC
8-K · Current reportFeb 26, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
8-K · Current reportFeb 3, 2026Current reportSEC
4 · Change in ownershipJan 29, 2026Insider tradeSEC
4 · Change in ownershipJan 29, 2026Insider tradeSEC
4 · Change in ownershipJan 29, 2026Insider tradeSEC
4 · Change in ownershipJan 15, 2026Insider tradeSEC
4 · Change in ownershipJan 15, 2026Insider tradeSEC
4 · Change in ownershipJan 15, 2026Insider tradeSEC
4 · Change in ownershipJan 15, 2026Insider tradeSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
4 · Change in ownershipNov 6, 2025Insider tradeSEC
4 · Change in ownershipNov 6, 2025Insider tradeSEC
3 · Initial statement of ownershipNov 6, 2025Insider tradeSEC
3 · Initial statement of ownershipNov 6, 2025Insider tradeSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
4 · Change in ownershipNov 4, 2025Insider tradeSEC
4 · Change in ownershipOct 30, 2025Insider tradeSEC
4 · Change in ownershipOct 30, 2025Insider tradeSEC
4 · Change in ownershipOct 30, 2025Insider tradeSEC
144 · Notice of proposed saleOct 29, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
4 · Change in ownershipJul 30, 2025Insider tradeSEC
4 · Change in ownershipJul 30, 2025Insider tradeSEC
4 · Change in ownershipJul 30, 2025Insider tradeSEC
4 · Change in ownershipJul 30, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 29, 2025Big-stake noticeSEC
4 · Change in ownershipJul 10, 2025Insider tradeSEC
4 · Change in ownershipJul 1, 2025Insider tradeSEC
4 · Change in ownershipJul 1, 2025Insider tradeSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 11, 2025Insider tradeSEC
8-K · Current reportJun 11, 2025Management or board changeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
8-K · Current reportJun 6, 2025Meeting outcomeSEC
8-K · Current reportJun 4, 2025Material contractSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 5, 2025Quarterly reportSEC
8-K · Current reportMay 5, 2025ResultsSEC
4 · Change in ownershipApr 30, 2025Insider tradeSEC
4 · Change in ownershipApr 30, 2025Insider tradeSEC
4 · Change in ownershipApr 30, 2025Insider tradeSEC
4 · Change in ownershipApr 30, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 30, 2025Big-stake noticeSEC
144 · Notice of proposed saleApr 29, 2025Other filingsSEC
144 · Notice of proposed saleApr 28, 2025Other filingsSEC
4 · Change in ownershipApr 24, 2025Insider tradeSEC
ARS · Annual report to shareholdersApr 23, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 23, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 23, 2025Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 17, 2025Big-stake noticeSEC
4 · Change in ownershipMar 31, 2025Insider tradeSEC
4 · Change in ownershipMar 31, 2025Insider tradeSEC
4 · Change in ownershipMar 31, 2025Insider tradeSEC
4 · Change in ownershipMar 31, 2025Insider tradeSEC
144 · Notice of proposed saleMar 27, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeMar 20, 2025Big-stake noticeSEC
S-8 · Registration statement for employee plansFeb 26, 2025Offer documentSEC
10-K · Annual reportFeb 26, 2025Annual reportSEC
8-K · Current reportFeb 26, 2025ResultsSEC
4 · Change in ownershipFeb 13, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2025Big-stake noticeSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
144 · Notice of proposed saleJan 29, 2025Other filingsSEC
144 · Notice of proposed saleJan 28, 2025Other filingsSEC
4 · Change in ownershipJan 23, 2025Insider tradeSEC
144 · Notice of proposed saleJan 23, 2025Other filingsSEC
144 · Notice of proposed saleJan 22, 2025Other filingsSEC
144 · Notice of proposed saleJan 21, 2025Other filingsSEC
4 · Change in ownershipJan 14, 2025Insider tradeSEC
4 · Change in ownershipJan 14, 2025Insider tradeSEC
4 · Change in ownershipJan 14, 2025Insider tradeSEC
4 · Change in ownershipJan 14, 2025Insider tradeSEC
4 · Change in ownershipJan 14, 2025Insider tradeSEC
8-K · Current reportJan 13, 2025Current reportSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
144 · Notice of proposed saleJan 6, 2025Other filingsSEC
144 · Notice of proposed saleJan 3, 2025Other filingsSEC
4 · Change in ownershipDec 31, 2024Insider tradeSEC
4 · Change in ownershipDec 31, 2024Insider tradeSEC
4 · Change in ownershipDec 31, 2024Insider tradeSEC
4 · Change in ownershipDec 31, 2024Insider tradeSEC
144 · Notice of proposed saleDec 27, 2024Other filingsSEC
4 · Change in ownershipDec 18, 2024Insider tradeSEC
144 · Notice of proposed saleDec 16, 2024Other filingsSEC
8-K · Current reportDec 11, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2024Quarterly reportSEC
8-K · Current reportNov 6, 2024ResultsSEC
4 · Change in ownershipOct 30, 2024Insider tradeSEC
4 · Change in ownershipOct 30, 2024Insider tradeSEC
4 · Change in ownershipOct 30, 2024Insider tradeSEC
4 · Change in ownershipOct 30, 2024Insider tradeSEC
144 · Notice of proposed saleOct 29, 2024Other filingsSEC
144 · Notice of proposed saleOct 28, 2024Other filingsSEC
4 · Change in ownershipOct 1, 2024Insider tradeSEC
4 · Change in ownershipOct 1, 2024Insider tradeSEC
4 · Change in ownershipOct 1, 2024Insider tradeSEC
4 · Change in ownershipOct 1, 2024Insider tradeSEC
144 · Notice of proposed saleSep 27, 2024Other filingsSEC
8-K · Current reportSep 11, 2024Material contractSEC
424B5 · ProspectusSep 11, 2024Offer documentSEC
424B5 · ProspectusSep 9, 2024Offer documentSEC

This page holds 200 of 562 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Relay Therapeutics, Inc.’s releases · as of Oct 30, 2026

Common shares
220,959,470
Fully diluted
220,959,470

Fully diluted

LineSharesAs of
Common shares220,959,470Oct 30, 2026

Share count over time

CountShares
Oct 30, 2026220,959,470

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
T. Rowe Price24.5MUS$442MSep 30, 2026
Fidelity24.2MUS$438MSep 30, 2026
Sb Investment Advisers (UK) LTD21.9MUS$395MSep 30, 2026
BlackRock16.7MUS$301MSep 30, 2026
Casdin Capital, LLC16MUS$289MSep 30, 2026
Vanguard12.8MUS$232MSep 30, 2026
Perceptive Advisors LLC12.7MUS$230MSep 30, 2026
Commodore Capital LP12MUS$217MSep 30, 2026
State Street9.15MUS$165MSep 30, 2026
Nextech Invest Ltd.6.78MUS$122MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Bellevue Group AG6.19MUS$112MSep 30, 2026
Geode Capital5.1MUS$92.1MSep 30, 2026
AllianceBernstein3.92MUS$70.7MSep 30, 2026
TCG Crossover Management, LLC3.78MUS$68.3MSep 30, 2026
Westfield Capital Management Co LP3.61MUS$65.2MSep 30, 2026
Siren, L.L.C.3.26MUS$58.9MSep 30, 2026
Dimensional3.18MUS$57.3MSep 30, 2026
Bank of America3.1MUS$56MSep 30, 2026
Spruce Street Capital LP2.98MUS$53.9MSep 30, 2026
Baker Bros. Advisors LP2.83MUS$51MSep 30, 2026
Kynam Capital Management, LP2.75MUS$49.7MSep 30, 2026
Morgan Stanley2.59MUS$46.8MSep 30, 2026
Mpm Bioimpact LLC2.37MUS$42.8MSep 30, 2026
Goldman Sachs2.29MUS$41.3MSep 30, 2026
Northern Trust2.03MUS$36.6MSep 30, 2026
Adage Capital Partners Gp, L.L.C.2.01MUS$36.2MSep 30, 2026
Pictet Asset Management Holding SA1.98MUS$36MSep 30, 2026
Franklin Templeton1.98MUS$35.7MSep 30, 2026
Polar Capital Holdings Plc1.79MUS$32.3MSep 30, 2026
Two Sigma1.76MUS$31.8MSep 30, 2026
Schwab1.63MUS$29.3MSep 30, 2026
Elmind Capital, LP1.47MUS$26.4MSep 30, 2026
Connor, Clark & Lunn Investment Management Ltd.1.45MUS$26.2MSep 30, 2026
Alphabet Inc.1.41MUS$25.5MSep 30, 2026
Panagora Asset Management Inc1.26MUS$22.8MSep 30, 2026
Foresite Capital Management IV, LLC1.25MUS$22.6MSep 30, 2026
AQR Capital Management LLC1.25MUS$22.5MSep 30, 2026
UBS1.04MUS$18.8MSep 30, 2026
Frazier Life Sciences Management, L.P.1.02MUS$18.3MSep 30, 2026
Woodline Partners LP919KUS$16.6MSep 30, 2026
Invesco889KUS$16MSep 30, 2026
Duquesne Family Office LLC853KUS$15.4MSep 30, 2026
Affinity Asset Advisors, LLC850KUS$15.3MSep 30, 2026
First Trust806KUS$14.5MSep 30, 2026
Timothy G. Youngquist 2020 Irrevocable Trust801KUS$14.5MSep 30, 2026
Squadron Capital Management LLC785KUS$14.2MSep 30, 2026
Congress Asset Management Co780KUS$14.1MSep 30, 2026
Raymond James Financial Inc767KUS$13.8MSep 30, 2026
Jupiter Asset Management LTD722KUS$13MSep 30, 2026
Eversept Partners, LP682KUS$12.3MSep 30, 2026

This page holds 50 of 251 holders. Open Shareholders

Funds

HolderSharesValueAs of
Vanguard Total Stock Market Index Fund6.8MUS$127MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF6.3MUS$118MJun 30, 2026
iShares Russell 2000 ETF4.16MUS$77.9MJun 30, 2026
Vanguard Extended Market Index Fund1.94MUS$36.4MJun 30, 2026
Fidelity Small Cap Growth Fund1.92MUS$36.1MJul 31, 2026
Fidelity Advisor Biotechnology Fund1.85MUS$34.8MJul 31, 2026
T. Rowe Price Health Sciences Fund, Inc.1.84MUS$34.4MJun 30, 2026
Fidelity Small Cap Index Fund1.77MUS$33.3MJul 31, 2026
Harbor Small Cap Growth Fund1.68MUS$31.7MJul 31, 2026
Fidelity Stock Selector Small Cap Fund1.68MUS$31.6MJul 31, 2026
Show 50 holders
HolderSharesValueAs of
Select Health Care Portfolio1.68MUS$23.6MMay 31, 2026
T. Rowe Price New Horizons Fund, Inc.1.57MUS$29.5MJun 30, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund1.37MUS$25.6MJun 30, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund1.29MUS$18.1MMay 31, 2026
iShares Russell 2000 Growth ETF1.13MUS$21.1MJun 30, 2026
Fidelity Advisor Health Care Fund1.04MUS$19.6MJul 31, 2026
iShares Biotechnology ETF1.02MUS$19MJun 30, 2026
Select Biotechnology Portfolio1.01MUS$14.2MMay 31, 2026
AB Small Cap Growth Portfolio997KUS$18.7MJun 30, 2026
Fidelity Small Cap Growth K6 Fund995KUS$18.7MJul 31, 2026
Fidelity Series Small Cap Opportunities Fund965KUS$18.2MJul 31, 2026
AB Discovery Growth Fund, Inc.877KUS$16.4MJun 30, 2026
Vanguard Explorer Fund865KUS$16.3MJul 31, 2026
Fidelity Extended Market Index Fund801KUS$11.3MMay 31, 2026
Vanguard Russell 2000 Index Fund767KUS$10.8MMay 31, 2026
Schwab U.S. Small-Cap ETF744KUS$10.5MMay 31, 2026
T. Rowe Price Small-Cap Stock Fund, Inc.694KUS$13MJun 30, 2026
Fidelity U.S. Equity Central Fund690KUS$12.9MJun 30, 2026
U.S. Small Cap Portfolio667KUS$12.6MJul 31, 2026
Dimensional U.S. Small Cap ETF592KUS$11.2MJul 31, 2026
Franklin Small Cap Growth Fund568KUS$10.7MJul 31, 2026
U.S. Micro Cap Portfolio508KUS$9.56MJul 31, 2026
Fidelity Small Cap Discovery Fund486KUS$9.15MJul 31, 2026
First Trust Small Cap Growth AlphaDEX Fund469KUS$8.83MJul 31, 2026
Fidelity Small Cap Value Fund465KUS$8.76MJul 31, 2026
Fidelity Enhanced Small Cap Core ETF434KUS$8.13MJun 30, 2026
Fidelity Series Small Cap Discovery Fund424KUS$7.99MJul 31, 2026
JNL Multi-Manager Small Cap Value Fund405KUS$7.58MJun 30, 2026
Franklin Biotechnology Discovery Fund405KUS$7.63MJul 31, 2026
Fidelity SAI Small-Mid Cap Momentum Index Fund402KUS$7.58MJul 31, 2026
Small Cap Value Fund396KUS$7.42MJun 30, 2026
EQ/AB Small Cap Growth Portfolio393KUS$7.36MJun 30, 2026
Schwab Small-Cap Index Fund393KUS$7.39MJul 31, 2026
Vanguard Strategic Equity Fund390KUS$7.29MJun 30, 2026
Avantis U.S. Small Cap Equity ETF389KUS$5.47MMay 31, 2026
Vanguard Health Care Index Fund384KUS$5.4MMay 31, 2026
VIP Health Care Portfolio376KUS$7.03MJun 30, 2026
T. Rowe Price Institutional Small-Cap Stock Fund374KUS$7MJun 30, 2026
BlackRock Health Sciences Opportunities Portfolio343KUS$4.82MMay 29, 2026
Dimensional U.S. Core Equity 2 ETF319KUS$6MJul 31, 2026

This page holds 50 of 277 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Patel Sanjiv
Director, Officer: President and CEO
Sale48,202USD 16.13US$777KNov 19, 2026
Catinazzo Thomas
Officer: Chief Financial Officer
Sale32,717USD 16.51US$540KNov 18, 2026
Bergstrom Donald A
Officer: President, R&D
Sale10,269USD 16.51US$170KNov 18, 2026
Catinazzo Thomas
Officer: Chief Financial Officer
Sale1,469USD 18.62US$27,353Oct 28, 2026
Bergstrom Donald A
Officer: President, R&D
Sale2,252USD 18.62US$41,932Oct 28, 2026
Rahmer Peter
Officer: See remarks
Sale753USD 18.62US$14,021Oct 28, 2026
Patel Sanjiv
Director, Officer: President and CEO
Sale48,199USD 18.10US$872KOct 7, 2026
Catinazzo Thomas
Officer: Chief Financial Officer
Sale17,511USD 18.58US$325KOct 6, 2026
Catinazzo Thomas
Officer: Chief Financial Officer
Sale206USD 19.26US$3,968Oct 6, 2026
Patel Sanjiv
Director, Officer: President and CEO
Sale48,199USD 18.94US$913KSep 8, 2026
All 34 trades
TradeTradeSharesPriceValueDate
Catinazzo Thomas
Officer: Chief Financial Officer
Sale17,717USD 18.94US$336KSep 8, 2026
Bergstrom Donald A
Officer: President, R&D
Sale8,530USD 18.97US$162KSep 8, 2026
Rahmer Peter
Officer: See remarks
Sale4,508USD 20.03US$90,295Aug 26, 2026
Sb Investment Advisers (UK) LTD
10% owner
Sale6,000,000USD 19.40US$116MAug 25, 2026
Patel Sanjiv
Director, Officer: President and CEO
Sale48,199USD 20.33US$980KAug 17, 2026
Catinazzo Thomas
Officer: Chief Financial Officer
Sale17,717USD 19.74US$350KAug 14, 2026
Bergstrom Donald A
Officer: President, R&D
Sale2,237USD 18.61US$41,631Jul 28, 2026
Rahmer Peter
Officer: See remarks
Sale748USD 18.61US$13,920Jul 28, 2026
Catinazzo Thomas
Officer: Chief Financial Officer
Sale1,459USD 18.61US$27,152Jul 28, 2026
Patel Sanjiv
Director, Officer: President and CEO
Sale48,199USD 19.58US$944KJul 7, 2026
Catinazzo Thomas
Officer: Chief Financial Officer
Sale17,717USD 18.69US$331KJul 6, 2026
Bergstrom Donald A
Officer: President, R&D
Sale8,660USD 18.71US$162KJul 6, 2026
Rahmer Peter
Officer: See remarks
Sale50,000USD 19.09US$955KJun 30, 2026
Bergstrom Donald A
Officer: President, R&D
Sale93,456USD 16.94US$1.58MJun 22, 2026
Catinazzo Thomas
Officer: Chief Financial Officer
Sale17,717USD 17.01US$301KJun 22, 2026
Catinazzo Thomas
Officer: Chief Financial Officer
Sale56,323USD 16.97US$956KJun 22, 2026
Catinazzo Thomas
Officer: Chief Financial Officer
Sale61,563USD 16.97US$1.04MJun 22, 2026
Catinazzo Thomas
Officer: Chief Financial Officer
Sale51,560USD 16.97US$875KJun 22, 2026
Catinazzo Thomas
Officer: Chief Financial Officer
Sale17,717USD 12.86US$228KMay 14, 2026
Bergstrom Donald A
Officer: President, R&D
Sale1,490USD 14.79US$22,037Apr 28, 2026
Rahmer Peter
Officer: See remarks
Sale753USD 14.79US$11,137Apr 28, 2026
Catinazzo Thomas
Officer: Chief Financial Officer
Sale972USD 14.79US$14,376Apr 28, 2026
Catinazzo Thomas
Officer: Chief Financial Officer
Sale1,800USD 15.00US$27,000Apr 9, 2026
Catinazzo Thomas
Officer: Chief Financial Officer
Sale17,717USD 13.01US$230KApr 7, 2026

Big stakes

StakeStakeSharesDateFiling
FMR LLC10.00%21.3MJul 31, 2026Schedule 13G
Sb Investment Advisers (UK) LTD9.90%21.9MSep 30, 2026Schedule 13G
T. Rowe Price Investment Management, Inc.8.20%17.9MSep 30, 2026Schedule 13G
Casdin Capital, LLC7.50%13MDec 31, 2025Schedule 13G
Perceptive Advisors LLC6.40%14.1MJun 30, 2026Schedule 13G
BlackRock, Inc.6.10%10.3MMar 31, 2025Schedule 13G
Commodore Capital LP5.50%12MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Habib Joseph Dable
Other companies: Tyra Biosciences, Inc. (Director · Since at least Apr 16, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Day One Biopharmaceuticals Inc (Director · Since at least Jan 17, 2024); PepGen Inc. (Director · Since at least Sep 20, 2022); Blueprint Medicines Corp (Director · Since at least Jun 23, 2022); Jade Biosciences, Inc. (Director · Jul 10, 2023 – Jun 5, 2024 · Past); Albireo Pharma Inc (Director · Aug 8, 2022 – Mar 2, 2023 · Past); Acceleron Pharma Inc (CEO and President, Director · Jan 4, 2021 – Nov 19, 2021 · Past)
Director · Since at least Nov 4, 2025
Alexis Borisy
Other companies: Parabilis Medicines, Inc. (Lead Independent Director; Chairman, Nextech Invest; Chairman, Curie.Bio · Since at least Jun 9, 2026); Revolution Medicines, Inc. (Director · Since at least Jun 26, 2025); Blueprint Medicines Corp (Director · Since at least Jun 18, 2025); Tango Therapeutics, Inc. (Director · Since at least Jun 5, 2025)
Director · Since at least Jun 6, 2025
Lonnel Coats
Other companies: Mineralys Therapeutics, Inc. (Board Member · Since at least Oct 19, 2026); Verve Therapeutics Inc (Director · Since at least Aug 8, 2022); Blueprint Medicines Corp (Director · Since at least Feb 3, 2016); Lexicon Pharmaceuticals, Inc. (Chief Executive Officer, Director · Jul 7, 2014 – Feb 28, 2024 · Past)
Director · Since at least Nov 4, 2025
Laura Shawver
Other companies: ARS Pharmaceuticals, Inc. (Director · Since at least Dec 3, 2020); Nkarta, Inc. (Director · Jul 9, 2020 – Jun 8, 2022 · Past); Synthorx Inc (President and CEO, Director · Dec 6, 2018 – Jan 23, 2020 · Past)
Director · Jul 15, 2020 – Jun 3, 2024 · Past
Douglas S Ingram
Other companies: Arrowhead Pharmaceuticals, Inc. (Director · Since at least Dec 16, 2025); Sarepta Therapeutics, Inc. (Chief Executive Officer, Director · Since at least Dec 7, 2025)
Director · Since at least Jun 6, 2025
Sekar Kathiresan
Other companies: Maze Therapeutics, Inc. (Director · Since at least Jan 30, 2025); Verve Therapeutics Inc (Chief Executive Officer, Director · Since at least Jun 16, 2021)
Director · Since at least Jul 25, 2022
Claire Mazumdar
Other companies: Bicara Therapeutics Inc. (Chief Executive Officer · Since at least Sep 12, 2024)
Director · Since at least Jun 9, 2025
Andy PorterChief Administrative Officer · Dec 17, 2021 – Oct 28, 2022 · Past
Don BergstromPresident, R&D · Since at least May 19, 2026
Eunice KwakSVP, Breast Cancer Global Medical Lead · Since at least Nov 5, 2026
All 21 people
PersonSeat
Imogen PryceChief Operating Officer, R&D · Since at least Nov 5, 2026
Jim WattersChief Scientific Officer · Since at least Nov 4, 2026
Linda A HillDirector · Since at least Jun 6, 2025
Mahesh PadvalChief Pharmaceutical Development Officer · Since at least Nov 5, 2026
Mark MurckoDirector · Since at least Jun 3, 2024
Peter RahmerChief Corporate Development Officer · Since at least Nov 5, 2026
Sanjiv K. PatelPresident & Chief Executive Officer · Since at least Aug 6, 2026
Shannon CampbellHead of Commercial · Since at least Nov 4, 2026
Soo-Yeun LimSenior Vice President, General Counsel · Since at least Nov 5, 2026
Thomas CatinazzoChief Financial Officer · Since at least Apr 28, 2022
Tom CatinazzoChief Financial Officer · Since at least Oct 30, 2026

Open People

Log in to ask 6ix AI your own questions about Relay Therapeutics, Inc.